A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Romania- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Romania73 clinical trials in Constanta, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in RomaniaStudii.Clinice.ro(opens in a new tab)
Romania
Romania
Romania
Romania
Romania
Romania
Romania
Romania
Romania
Romania
Romania
RomaniaThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical research focusing on multiple sclerosis treatments, including studies of remibrutinib and tolebrutinib for both relapsing and progressive forms. Additional trials investigate therapies for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Studies aim to evaluate long-term safety and efficacy of novel therapeutic approaches.
Comprehensive research into viral infections, including studies on COVID-19 treatments and HIV-1 management. Trials evaluate new therapeutic options for respiratory syncytial virus (RSV) prevention in infants.
Focus on developing both treatment and preventive strategies for viral diseases.
Studies investigating treatments for Sjögren's Disease and inflammatory bowel conditions like Crohn's Disease. Research includes evaluation of novel therapies such as mirikizumab and MORF-057.
Trials focus on improving disease management and patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.